Literature DB >> 20087166

Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis.

Mohammad F Madhoun1, Javid Fazili, Brianna C Bright, Ted Bader, David N Roberts, Michael S Bronze.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) occurring in "noncirrhotic" hepatitis C virus (HCV)-infected patients has been reported; but the exact prevalence or incidence has not been described before.
METHODS: We conducted a systematic review of literature: Ovid was used to search the literature from January 1, 1990, to September 1, 2008. Articles containing "HCC" keywords (hepatocellular carcinoma, hepatoma, liver cancer) were combined with the word "cirrhosis" or "fibrosis" and with "absence" keywords [noncirrhotic, absence, without]. Two hundred articles were selected and screened according to predesigned exclusion and inclusion criteria.
RESULTS: Nineteen articles met the inclusion criteria. The estimated prevalence of noncirrhotic HCC ranged from 6.7% to 50.1%. The pooled prevalence estimates for HCV in noncirrhotic HCC ranged from 0% and 68.4% according to the geographic location. Reports from Japan had the highest estimated pooled prevalence of HCV (55.01%) followed by Italy (29.95%).
CONCLUSION: HCV can occur in patients with HCC without cirrhosis, but the true incidence and prevalence are very difficult to ascertain. Further studies are needed to define this group of patients.

Entities:  

Mesh:

Year:  2010        PMID: 20087166     DOI: 10.1097/MAJ.0b013e3181c4af27

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  10 in total

1.  Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.

Authors:  Chansoo Moon; Kyu Sik Jung; Do Young Kim; Oidov Baatarkhuu; Jun Yong Park; Beom Kyung Kim; Seung Up Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Dig Dis Sci       Date:  2014-09-19       Impact factor: 3.199

Review 2.  Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges.

Authors:  Michael J Bouchard; Sonia Navas-Martin
Journal:  Cancer Lett       Date:  2010-12-18       Impact factor: 8.679

3.  Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.

Authors:  Hui Liu; Peng Li; Yun Zhai; Chun-Feng Qu; Li-Jie Zhang; Yu-Fen Tan; Ning Li; Hui-Guo Ding
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

4.  Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients.

Authors:  Mazen Albeldawi; Mohamed Soliman; Rocio Lopez; Nizar N Zein
Journal:  Dig Dis Sci       Date:  2012-06-14       Impact factor: 3.199

Review 5.  Burden of pediatric hepatitis C.

Authors:  Mortada Hassan El-Shabrawi; Naglaa Mohamed Kamal
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

6.  Practice, Knowledge, and Barriers for Screening of Hepatocellular Carcinoma Among High-Risk Chinese Patients.

Authors:  Kerui Xu; Shinobu Watanabe-Galloway; Fedja A Rochling; Jianjun Zhang; Paraskevi A Farazi; Hongyan Peng; Hongmei Wang; Jiangtao Luo
Journal:  Ann Glob Health       Date:  2017-04-19       Impact factor: 2.462

7.  Molecular pathology of hepatic neoplasms: classification and clinical significance.

Authors:  Zenta Walther; Dhanpat Jain
Journal:  Patholog Res Int       Date:  2011-04-07

8.  Oncogenic potential of hepatitis C virus proteins.

Authors:  Arup Banerjee; Ratna B Ray; Ranjit Ray
Journal:  Viruses       Date:  2010-09-27       Impact factor: 5.818

Review 9.  The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.

Authors:  Christine Hong Ting Yang; Eric R Yoo; Aijaz Ahmed
Journal:  J Clin Transl Hepatol       Date:  2017-02-07

Review 10.  Current Imaging Diagnosis of Hepatocellular Carcinoma.

Authors:  Evangelos Chartampilas; Vasileios Rafailidis; Vivian Georgopoulou; Georgios Kalarakis; Adam Hatzidakis; Panos Prassopoulos
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.